NCT04027790 is a clinical trial of Epi proColon in Colo-rectal Cancer, sponsored by Epigenomics, Inc.

Who is sponsoring NCT04027790?

NCT04027790 is sponsored by Epigenomics, Inc.

What drugs are being tested in NCT04027790?

Interventions in NCT04027790: Epi proColon.

What condition does NCT04027790 study?

NCT04027790 studies Colo-rectal Cancer.

Is NCT04027790 still recruiting?

NCT04027790 is currently completed. Last updated 2 February 2021.

Last reviewed 2021-02-02 · How we verify

NCT04027790

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plasma-based Colorectal Cancer Screening Research & Development

Completed Last updated 2 February 2021

What this trial tests

trial testing Epi proColon in Colo-rectal Cancer in 354 participants. Completed in 31 March 2020.

Timeline

3 May 2019

Primary endpoint
31 March 2020

31 March 2020

Quick facts

Lead sponsor	Epigenomics, Inc
Status	Completed
Study type	OBSERVATIONAL
Enrollment	354
Start date	3 May 2019
Primary completion	31 March 2020
Estimated completion	31 March 2020
Sites	5 locations across United States

Drugs / interventions tested

Epi proColon

Conditions studied

Colo-rectal Cancer — all drugs for Colo-rectal Cancer →

Sponsor

Epigenomics, Inc

Who can join

Adults 45 to 84, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this Clinical Sample Collection Study is to develop a biobank of appropriately collected plasma samples from colorectal cancer patients (i.e. AJCC/UICC stages 0, I, II, III) prior to therapeutic intervention, and from people reporting for colorectal cancer screening by colonoscopy, prior to bowel preparation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Progress in Clinical Research in Secondary Prevention and Early Detection of Colorectal Cancer.
Partyka O, Pajewska M, Czerw A, Deptała A, et al · · 2025 · cited 2× · PMID 39941735 · DOI 10.3390/cancers17030367

Verify or expand the search:

Other recruiting trials for Colo-rectal Cancer

Currently open trials in the same condition.

NCT06645015 — The AIDPRO-CRC Trial · NA · recruiting
NCT07145255 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07085169 — Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC · Phase 2 · recruiting
NCT06880055 — Shield Post-Approval Study Protocol · recruiting
NCT06905925 — The Effect of the Training Program Given to Permanent Colostomy Patients on Self-efficacy · NA · recruiting

Other Epigenomics, Inc trials

Trials by the same sponsor.

NCT03804593 — HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04027790 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Epigenomics, Inc
Last refreshed: 2 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04027790.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing